Key points from article :
Rejuvenate Biomed announces breakthrough Phase 1b trial results of its lead candidate RJx-01 for the treatment of sarcopenia.
RJx-01 is an orally drug with synergetic effects of 2 molecules - metformin and galantamine
Total of 42 healthy male subjects aged 65 to 75 with disuse-induced sarcopenia received RJx-01 treatment for 6 weeks.
Muscle strength recovery was better in the RJx-01 group compared to placebo.
Leg acceleration, crucial for daily activities and preventing falls, improved with RJx-01.
Participants receiving RJx-01 experienced less fatigue during leg exercises.
“We anticipate advancing Phase 2 program later this year, aiming to substantiate RJx-01’s therapeutic potential in addressing sarcopenia and osteoporosis,” - Ann Belien, CEO of Rejuvenate Biomed.
Exploring partnership opportunities to combine RJx-01 with GLP-1 drugs for obesity and diabetes type 2.
Positive results support Rejuvenate Biomed's drug discovery platforms for age-related diseases.
